期刊
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
卷 39, 期 6, 页码 712-728出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0317167100015547
关键词
-
资金
- Canadian Institutes of Health Research [13129]
- Heart and Stroke Foundation Canada
- Alzheimer's Association, US
- Alzheimer Society of Canada
- National Institute of Health
- Canadian Stroke Network
- Alzheimer Society of Saskatchewan
- Alzheimer's Association
- Canadian Institutes of Health Research
- Scottish Rite Charitable Foundation of Canada
Alzheimer's disease (AD), considered the commonest neurodegenerative cause of dementia, is associated with hallmark pathologies including extracellular amyloid-beta protein (A beta) deposition in extracellular senile plaques and vessels, and intraneuronal tau deposition as neurofibrillary tangles. Although AD is usually categorized as neurodegeneration distinct from cerebrovascular disease (CVD), studies have shown strong links between AD and CVD. There is evidence that vascular risk factors and CVD may accelerate A beta 40-42 production/ aggregation/deposition and contribute to the pathology and symptomatology of AD. A beta deposited along vessels also causes cerebral amyloid angiopathy. Amyloid imaging allows in vivo detection of AD pathology, opening the way for prevention and early treatment, if disease-modifying therapies in the pipeline show safety and efficacy. In this review, we review the role of vascular factors and A beta, underlining that vascular risk factor management may be important for AD prevention and treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据